A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Histologically or cytologically documented squamous non-small cell lung cancer (NSCLC).

• Stage IV metastatic non-small cell lung cancer (mNSCLC) (based on the American JointCommittee on Cancer Edition 8) not amenable to curative treatment.

• Absence of documented tumor genomic mutation results from tests conducted as part ofstandard local practice in any actionable driver oncogenes for which there arelocally approved targeted first-line (1L) therapies.

• Provision of acceptable tumor sample to confirm tumor programmed death-ligand 1 (PD-L1) expression tumor cells (TC) ≥ 1%.

• At least one lesion not previously irradiated that qualifies as a ResponseEvaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) target lesion (TL) atbaseline and can be accurately measured at baseline as ≥ 10 mm in the longestdiameter (except lymph nodes, which must have short axis ≥ 15 mm) with computedtomography (CT) or magnetic resonance imaging (MRI) and is suitable for accuraterepeated measurements.

• Adequate organ and bone marrow function.

Exclusion Criteria:

• Presence of small cell and neuroendocrine histology components.

• Brain metastases unless asymptomatic, stable, and not requiring steroids oranticonvulsants for at least 4 weeks prior to start of study intervention. A minimumof 2 weeks must have elapsed between the end of brain radiotherapy and studyenrollment. Participants must have recovered from the acute toxic effect ofradiotherapy (eg, dizziness and signs of increased intracranial pressure).

• Any prior systemic therapy received for advanced or metastatic non-small cell lungcancer (mNSCLC).

• Prior treatment with an anti-programmed cell death protein 1 (anti-PD-1) oranti-programmed death-ligand 1 (anti-PD-L1) agent.

• Any prior exposure to an anti-T-cell immunoglobulin and immunoreceptortyrosine-based inhibitory motif domain (anti-TIGIT) therapy or any other anticancertherapy targeting immune-regulatory receptors or mechanisms.

• History of another primary malignancy except for malignancy treated with curativeintent with no known active disease ≥ 2 years before the first dose of studyintervention and of low potential risk for recurrence.

• Active or prior documented autoimmune or inflammatory disorders requiring chronictreatment with steroids or other immunosuppressive treatment.

• Active primary immunodeficiency/active infectious disease(s).

• Active tuberculosis infection.